Gilead Sciences, Inc.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
Remdesivir brought in $873 million in the third quarter, the first full quarter the drug has been on the market. But the drug is facing a storm of controversy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Shares of Gilead Sciences are jumping in aftermarket trading following full approval for Veklury (remdesivir) as a treatment for COVID-19. The approval marks the first drug approved by the U.S. Food and Drug Administration as a treatment for the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
It was a moderately busy week for clinical trial news. Here’s a look.
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
JOBS
IN THE PRESS